Hexima (ASX:HXL) Institutional Ownership : 0.00% (As of May. 23, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Hexima Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hexima's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hexima's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hexima's Float Percentage Of Total Shares Outstanding is 0.00%.

Hexima Institutional Ownership Historical Data

The historical data trend for Hexima's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Institutional Ownership Chart

Hexima Annual Data

Trend

Jun08

Jun09

Jun10

Jun20

Jun21

Jun22

Jun23

Institutional Ownership

Get a 7-Day Free Trial

Hexima Semi-Annual Data
	Dec06	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Institutional Ownership	Get a 7-Day Free Trial										-	-	-	-	-

Hexima Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Hexima (ASX:HXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.hexima.com.au

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.